Norfolk, VA 的 乳癌 臨床試驗
16 項針對 乳癌 的研究正在 Norfolk（約 30 英里範圍內）及其周邊地點尋找參與者。開啟研究以查看參與資格及聯絡研究團隊的方式。
官方研究文本（英文）
正在為研究招募對象嗎？將此頁面置頂展示 — $99 / 30 天 →
The Vanguard Study: Testing a New Way to Screen for Cancer
招募中歡迎健康志工
- Sentara Norfolk General Hospital, Norfolk
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
招募中3 期
- Virginia Oncology Associates, Norfolk
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
招募中3 期
- Virginia Oncology Associates, Norfolk
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中觀察性研究歡迎健康志工
- Sentara Norfolk General Hospital, Norfolk
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
招募中2 期
- Virginia Oncology Associates, Norfolk
A Study of Patritumab Deruxtecan (HER3-DXd) in Combination With Trastuzumab Deruxtecan (T-DXd) in Participants With HR-Positive, HER2-Low or HER2-Ultralow Unresectable or Metastatic Breast Cancer
招募中1/2 期
- Virginia Oncology Associates, Norfolk
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
招募中3 期
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
招募中3 期
- Research Site, Norfolk
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
招募中3 期
- Virginia Oncology Associates (VOA) ( Site 8008), Norfolk
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
招募中3 期
- Clinical Trial Site, Norfolk
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)
招募中2 期
- Virginia Oncology Associates (VOA) ( Site 8001), Norfolk
Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer
招募中1/2 期
- Virginia Cancer Institute, Norfolk
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
招募中1/2 期
- Virginia Oncology Associates (Norfolk) - USOR, Norfolk
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
招募中3 期
- Virginia Oncology Associates, Norfolk
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
招募中1/2 期
- USOR Virginia Oncology Associates, Norfolk
Study of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer
招募中2 期
- Virginia Oncology Associates, Norfolk
其他城市的 乳癌 試驗
- New York City, NY136 項研究
- Houston, TX126 項研究
- Boston, MA112 項研究
- Nashville, TN81 項研究
- Los Angeles, CA73 項研究
- Edison, NJ68 項研究
- St. Louis, MO64 項研究
- Queens, NY64 項研究
- Durham, NC64 項研究
- Chicago, IL59 項研究
- Philadelphia, PA56 項研究
- Dallas, TX55 項研究
Norfolk 的其他研究
- 膀胱癌8 項研究
- 前列腺癌8 項研究
- 腹主動脈瘤7 項研究
- 卵巢癌7 項研究
- 非小細胞肺癌7 項研究
- 癌症（所有類型）7 項研究
- 心臟衰竭7 項研究
- 心血管疾病7 項研究
- 脊髓性肌肉萎縮症6 項研究
- 周邊動脈疾病5 項研究
- 三陰性乳癌5 項研究
- 急性髓系白血病5 項研究
資料來源：ClinicalTrials.gov，擷取日期 2026年10月6日。各研究自行設定資格標準；由研究團隊決定參與者資格。